Navigation Links
Repros Reports That Proellex Has Demonstrated Superior Efficacy and,Safety in Endometriosis When Compared to Standard of Drug Care

three and this was maintained through month six of treatment. This outcome was associated with a statistically significant increase (p = 0.023) in biomarkers of bone resorption compared with the baseline values and at month three, and therefore an increased risk of bone loss. At month six as well as at the one month follow up visit, this increase in markers of bone resorption was still present in women treated with Lucrin.

Side effects of Proellex were generally mild with no individual organ system being involved systematically. This is a small study and no definitive conclusions can be made from the safety data but there was no single signal of safety observed.

Safety evaluations also included ultrasound examinations of endometrial thickness. The data from these examinations suggest an inverse dose dependent effect of Proellex on endometrial thickness at three months. After three months on treatment, women receiving 50mg Proellex had a non-significant reduction in the thickness of the endometrium compared to baseline, whereas women receiving 12.5mg and 25mg Proellex had a non-significant thickening of the endometrium. This inverse relationship was still present at six months of treatment although there was some increase in endometrial thickness as compared to baseline for all three doses of Proellex at that time. In two cases where non-menstrual spotting and bleeding was observed in patients with excessive endometrial thickening in the 12.5mg and 25mg groups, a dilation and curettage (D&C) procedure was performed to stop the bleeding. A similar event has not been seen at the 50mg dose during the treatment phase. Greater than normal bleeding occurred in two patients in the 50mg Proellex group after treatment was stopped and a D&C was performed in one and the other successfully managed conservatively.

Dr. Andre van As, Repros' Chief Medical Officer and Senior VP of Clinical and Regulatory Affairs, noted, "Although these data are from a s
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
3. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
4. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
5. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
6. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
7. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
8. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
9. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
10. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
11. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
Post Your Comments:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... 2014 Dynamic Healthcare Services, Inc. ("DHS"), a portfolio company ... Progressive Home Medical Equipment, Inc. ("Progressive") of Clarion, ... the acquisition were not disclosed. Progressive is ... wide range of sleep, mobility, and respiratory products to customers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... EAST SETAUKET, N.Y., Aug. 12 Lixte,Biotechnology Holdings, ... had filed a patent application for the use ... brain tumors as potential treatments for,neurodegenerative diseases including ... Kovach, President and CEO of Lixte, said, "Lixte ...
... DIEGO, Aug. 12 MabVax Therapeutics, Inc., ... focused,on the development and commercialization of novel ... the completion of two separate,licensing agreements with ... Cancer Research (SKI)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080812/LATU515LOGO ...
Cached Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2MabVax Therapeutics Closes Two Licensing Agreements With Sloan-Kettering Institute for Cancer Research 2
(Date:4/18/2014)... turns 160 years of neuroanatomy on its head. , ... essential for the fast transmission of impulses along the ... thought, according to a new work lead by Professor ... and the University,s Department of Stem Cell and Regenerative ... Department of Molecular and Cellular Biology. , "Myelin is ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
... statement of CEO Nancy Brown on the Senate passage of ... today by the American Heart Association: , , The ... ensure a healthier future for our children with passage of ... legislation will allow us to protect them from a dirty ...
... Senators Vote for Historic Bill to Regulate Tobacco Products ... for Tobacco-Free Kids applauds U.S. Senator Richard Durbin for leading ... that gives the U.S. Food and Drug Administration (FDA) authority ... on tobacco marketing and sales to kids. , , ...
... June 11 The Campaign for Tobacco-Free Kids ... in the U.S. Senate to pass historic legislation that gives ... tobacco products, including the authority to crack down on tobacco ... the bipartisan bill 79 to 17. The House has ...
... Scheduled for Friday, June 12, 2009 , , LANCASTER, ... ) today reported financial results for the third quarter ended May ... the thirteen weeks ended May 3, 2009 were approximately $41.8 million, ... ended May 4, 2008. , , Income from continuing operations ...
... DALLAS, June 11 Zix Corporation (ZixCorp(R)), ... encryption services and payor sponsored e-Prescribing services, announced today ... assist ZixCorp,s Board of Directors in investigating strategic alternatives ... This strategic review may result in a partnership, ...
... Calif., June 11 Bionovo, Inc. (Nasdaq: BNVI ... 10, 2009 has denied all claims against the company and ... , The decision was in reference to a suit ... fraud, negligent misrepresentation and breach of oral contract stemming from ...
Cached Medicine News:Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 2Health News:Senator Durbin Leads Fight to Protect America's Kids from Tobacco 3Health News:Senator Reid Leads Fight to Protect America's Kids From Tobacco 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 2Health News:Herley Industries, Inc. Reports Third Quarter Earnings 3Health News:Herley Industries, Inc. Reports Third Quarter Earnings 4Health News:Herley Industries, Inc. Reports Third Quarter Earnings 5Health News:Herley Industries, Inc. Reports Third Quarter Earnings 6Health News:Herley Industries, Inc. Reports Third Quarter Earnings 7Health News:Herley Industries, Inc. Reports Third Quarter Earnings 8Health News:Herley Industries, Inc. Reports Third Quarter Earnings 9Health News:Herley Industries, Inc. Reports Third Quarter Earnings 10Health News:Herley Industries, Inc. Reports Third Quarter Earnings 11Health News:Herley Industries, Inc. Reports Third Quarter Earnings 12Health News:Zix Corporation Announces Review of Strategic Alternatives for e-Prescribing Business 2Health News:Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer - All Claims Denied 2
Stab incision blades color coded for simple and accurate identification...
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
... has two perforations which enable ... various single or bilateral configurations ... drape has two perforations which ... to various single or bilateral ...
30, 6.0mm from end...
Medicine Products: